Non-invasive Measures of Effects of Xolair in Asthma
Status:
Terminated
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at the effectiveness of Xolair® (omalizumab) in people
with asthma taking Advair Diskus®. The study will look at the effects of Xolair® on lung
function using high resolution computed tomography (HRCT) scans after asthma symptoms are
induced with a special substance called methacholine. This study is only taking place at
UCLA, where about 13 subjects will be enrolled. Participation requires 10-14 visits over
about 26 weeks.
Subjects will receive an albuterol inhaler to use as needed for immediate relief of symptoms
and fluticasone 250 mcg/salmeterol 50 mcg or fluticasone 500 mcg/salmeterol 50 mcg (Advair
Diskus® 250/50 or 500/50) to be taken twice daily. At certain visits, they will be given
Xolair® injections followed by various assessments, including CT scans and lung function
tests.